Related Experiment Videos
Cryptococcal meningitis in the acquired immunodeficiency syndrome
1Department of Medicine, University of California, San Francisco 94102.
Abstract:
Cryptococcosis is the most common, deep-seated fungal infection in AIDS patients, and cryptococcal meningitis is the most frequently observed syndrome. AIDS patients with cryptococcal meningitis usually have an indolent presentation and nonspecific findings on physical examination. Routine laboratory tests are of little assistance in diagnosing cryptococcal meningitis. Cerebrospinal fluid (CSF) white blood cell counts tend to be low, and glucose and protein levels are nonspecific. Serum cryptococcal antigen (CRAG) is a sensitive test for cryptococcal meningitis, and CSF CRAG is usually also positive. Definitive diagnosis is made by culture of the CSF. Therapy of cryptococcal meningitis is changing to antifungal agents that are easy to administer as outpatient therapy. Amphotericin B continues to be the primary antifungal used in initial treatment of cryptococcal meningitis; addition of flucytosine is of no benefit. Recent data suggest oral fluconazole is effective as primary therapy, and may be superior to amphotericin B as maintenance therapy. Maintenance therapy decreases the incidence of relapse and increases survival.
Insights
Cryptococcal meningitis, a common fungal infection in AIDS patients, presents subtly and is difficult to diagnose with routine tests. Newer antifungal therapies like oral fluconazole offer effective outpatient treatment and improve survival rates.
Area of Science:
- Infectious Diseases
- Mycology
- Immunocompromised Host Infections
Background:
- Cryptococcosis is a significant opportunistic infection in individuals with Acquired Immunodeficiency Syndrome (AIDS).
- Cryptococcal meningitis is the most prevalent clinical manifestation, often presenting with subtle symptoms and non-specific physical findings.
- Standard laboratory diagnostics frequently yield inconclusive results for cryptococcal meningitis in AIDS patients.
Purpose of the Study:
- To review the diagnostic challenges and evolving therapeutic strategies for cryptococcal meningitis in the context of AIDS.
- To highlight the utility of cryptococcal antigen testing and the role of cerebrospinal fluid cultures in diagnosis.
- To discuss current and emerging antifungal treatment options, emphasizing outpatient management and long-term outcomes.
Main Methods:
- Review of current literature on cryptococcosis and cryptococcal meningitis in AIDS patients.
- Analysis of diagnostic methods, including cerebrospinal fluid (CSF) analysis and antigen detection.
- Evaluation of antifungal therapies, including Amphotericin B, flucytosine, and fluconazole.
Main Results:
- Cryptococcal meningitis in AIDS patients often has an indolent course with non-specific clinical and laboratory findings.
- Serum and CSF cryptococcal antigen (CRAG) tests are sensitive diagnostic markers, while CSF culture remains the gold standard.
- Amphotericin B is a primary treatment, but oral fluconazole shows promise for both initial and maintenance therapy, potentially improving survival and reducing relapse rates.
Conclusions:
- Effective diagnosis of cryptococcal meningitis in AIDS relies on antigen testing and CSF culture, overcoming limitations of routine tests.
- Antifungal therapy is shifting towards outpatient-friendly options, with fluconazole emerging as a key agent for maintenance therapy.
- Optimized antifungal strategies, including maintenance therapy, are crucial for reducing relapse and improving survival in AIDS patients with cryptococcal meningitis.